Elisa Cerqui

2.3k total citations
19 papers, 285 citations indexed

About

Elisa Cerqui is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Elisa Cerqui has authored 19 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 7 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Elisa Cerqui's work include Acute Myeloid Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Elisa Cerqui is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Elisa Cerqui collaborates with scholars based in Italy and Germany. Elisa Cerqui's co-authors include Giuseppe Rossi, Erika Borlenghi, Chiara Pagani, Angela Passi, Simona Sica, Francesca Schieppati, Chiara Cattaneo, Francesco Lo‐Coco, Giuseppina Ruggeri and Carlo Finelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Elisa Cerqui

18 papers receiving 284 citations

Peers

Elisa Cerqui
Comparison fields: 5 of 42
  • Hematology 203
  • Molecular Biology 91
  • Genetics 83
  • Oncology 59
  • Epidemiology 50
Replace Giuseppina Loglisci with:
Giuseppina Loglisci Italy
Federica Lessi Italy
Kazuya Ishiwata Japan
M.L. Martino Spain
José Falantes Spain
Stefano D’Ardìa Italy
Nadira Duraković Croatia
Radwan Massoud Lebanon
Sigrid Machherndl‐Spandl Austria
Felipe Sandoval United States
Giuseppina Loglisci Italy View profile →
Citations per field, relative to Elisa Cerqui
Elisa Cerqui · 1×
Citations per year, relative to Elisa Cerqui
Elisa Cerqui · 1×

Countries citing papers authored by Elisa Cerqui

Since Specialization
Citations

This map shows the geographic impact of Elisa Cerqui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Cerqui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Cerqui more than expected).

Fields of papers citing papers by Elisa Cerqui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Cerqui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Cerqui. The network helps show where Elisa Cerqui may publish in the future.

Co-authorship network of co-authors of Elisa Cerqui

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Cerqui. A scholar is included among the top collaborators of Elisa Cerqui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Cerqui. Elisa Cerqui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
# Work Indexed citations
1
Impact of Infectious Complications Should be Considered When Choosing Chemotherapy for Elderly Acute Myeloid Leukemia Fit Patients: Results of a Large Monocentric Retrospective Study
2024 ·Blood ·Erika Borlenghi, Irene Terrenato, Margherita Oberti, (unknown), Angelica Spolzino, Elisa Cerqui, (unknown), (unknown), (unknown), (unknown), Diego Bertoli, Francesco Marchesi, Giuseppe Rossi, Alessandra Tucci
0
2
Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center Experience
2022 ·Cancers ·Erika Borlenghi, Chiara Cattaneo, Diego Bertoli, Elisa Cerqui, Silvana Archetti, Angela Passi, Margherita Oberti, (unknown), (unknown), Chiara Pagani, (unknown), Chiara Bottelli, (unknown), (unknown), Alessandra Tucci, Giuseppe Rossi
4
3
Validation of the “fitness criteria” for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)
2020 ·Journal of Geriatric Oncology ·Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, Massimo Bernardi, (unknown), Roberto Cairoli, Nicola Fracchiolla, Elisabetta Todisco, Mauro Turrini, Chiara Cattaneo, Matteo Da Vià, Fabio Ciceri, Francesco Passamonti, Valentina Mancini, Mariarita Sciumé, Elisa Cerqui, (unknown), Giuseppe Rossi
13
4
Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia
2020 ·Hematological Oncology ·Erika Borlenghi, Chiara Cattaneo, Elisa Cerqui, Silvana Archetti, Diego Bertoli, Daniela Bellotti, (unknown), (unknown), Margherita Oberti, Francesca Schieppati, Chiara Pagani, Angela Passi, (unknown), Mirko Farina, Cecilia Carbone, Claudia Crippa, (unknown), Alessandra Tucci, Giuseppe Rossi
8
5
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome
2019 ·Leukemia Research ·Giulia Falconi, Emiliano Fabiani, Marianna Criscuolo, Luana Fianchi, Carlo Finelli, Elisa Cerqui, Elvira Pelosi, (unknown), Carmelo Gurnari, (unknown), Massimiliano Postorino, Luca Laurenti, Alfonso Piciocchi, Ugo Testa, Francesco Lo‐Coco, Maria Teresa Voso
4
6
The e13a2 BCR‐ABL transcript negatively affects sustained deep molecular response and the achievement of treatment‐free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors
2019 ·Cancer ·Mariella D’Adda, Mirko Farina, Francesca Schieppati, Erika Borlenghi, Chiara Bottelli, Elisa Cerqui, Samantha Ferrari, (unknown), Chiara Pagani, Angela Passi, (unknown), Alessandra Tucci, (unknown), Giuseppina Ruggeri, Giuseppe Rossi
46
7
Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome
2019 ·Leukemia & lymphoma ·Chiara Cattaneo, (unknown), Michele Malagola, Chiara Pagani, Erika Borlenghi, Elisa Cerqui, Angela Passi, (unknown), Simona Bernardi, Claudia Crippa, (unknown), Cecilia Carbone, (unknown), Alessandro Re, Domenico Russo, Giuseppe Rossi
12
8
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS
2019 ·HemaSphere ·Mirko Farina, Mariella D’Adda, (unknown), Nicola Polverelli, Sérgio Ferrari, Chiara Bottelli, (unknown), Elisa Cerqui, (unknown), Simona Bernardi, Domenico Russo, Giuseppe Rossi
1
9
Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol
2019 ·Leukemia & lymphoma ·Renato Bassan, (unknown), Sabina Chiaretti, Ernesta Audisio, Nicola Cascavilla, Stefania Paolini, Mario Delia, Elisa Cerqui, Caterina Micò, Francesco Fabbiano, Martina Canichella, Anna Maria Scattolin, (unknown), Francesca Paoloni, (unknown), Antonella Vitale, Irene Della Starza, Paola Fazi, Marco Vignetti, Robin Foà
1
10
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network
2018 ·Annals of Hematology ·Patrizia Zappasodi, Laura Marbello, Erika Borlenghi, (unknown), Massimo Bernardi, Nicola Fracchiolla, Valentina Mancini, Matteo Da Vià, (unknown), Elisa Cerqui, Virginia Valeria Ferretti, Barbara Rocca, (unknown), Mario Cazzola, Carlo Castagnola, Giuseppe Rossi
2
11
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
2018 ·Leukemia ·Giulia Falconi, Emiliano Fabiani, Alfonso Piciocchi, Marianna Criscuolo, Luana Fianchi, Elisa Rossi, Carlo Finelli, Elisa Cerqui, Tiziana Ottone, Alfredo Molteni, Matteo Parma, Stella Santarone, Anna Candoni, Simona Sica, Giuseppe Leone, Francesco Lo‐Coco, Maria Teresa Voso
24
12
An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors
2017 ·Blood ·Mariella D’Adda, Mirko Farina, Francesca Schieppati, Elisa Cerqui, Giuseppina Ruggeri, Samantha Ferrari, Chiara Bottelli, Chiara Pagani, Angela Passi, Giuseppe Rossi
3
13
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
2017 ·Annals of Oncology ·Maria Teresa Voso, Giuseppe Leone, Alfonso Piciocchi, Luana Fianchi, Stella Santarone, Anna Candoni, Marianna Criscuolo, Arianna Masciulli, Elisa Cerqui, Alfredo Molteni, Carlo Finelli, Matteo Parma, Antonella Poloni, Angelo Michele Carella, Francesco Spina, Agostino Cortelezzi, Flavia Salvi, Emilio Paolo Alessandrino, Alessandro Rambaldi, Simona Sica
39
14
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre “real-world” experience
2015 ·Leukemia & lymphoma ·Elisa Cerqui, (unknown), Francesca Schieppati, Erika Borlenghi, Chiara Pagani, Daniela Bellotti, (unknown), Leonardo Boiocchi, Alessandra Sottini, Luisa Imberti, Giuseppe Rossi
1
15
Postremission sequential monitoring of minimal residual disease by WT1 Q‐PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients
2015 ·Cancer Medicine ·Michele Malagola, Cristina Skert, Erika Borlenghi, Marco Chiarini, Chiara Cattaneo, Enrico Morello, Valeria Cancelli, Federica Cattina, Elisa Cerqui, Chiara Pagani, Angela Passi, Rossella Ribolla, Simona Bernardi, Viviana Giustini, (unknown), Giuseppina Ruggeri, Luisa Imberti, Luigi Caimi, Domenico Russo, Giuseppe Rossi
27
16
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes
2014 ·Journal of Clinical Oncology ·Fabio Efficace, Franco Mandelli, Giuseppe Avvisati, Francesco Cottone, Felicetto Ferrara, Eros Di Bona, Giorgina Specchia, Massimo Breccia, Alessandro Levis, Simona Sica, Olimpia Finizio, Maria Grazia Kropp, Giuseppe Fioritoni, Elisa Cerqui, Marco Vignetti, Sergio Amadori, Richard F. Schlenk, Uwe Platzbecker, Francesco Lo‐Coco
57
17
Relapsing bloodstream infections during treatment of acute leukemia
2013 ·Annals of Hematology ·Chiara Cattaneo, (unknown), Mario Tumbarello, Cristina Skert, Erika Borlenghi, Francesca Schieppati, Elisa Cerqui, Chiara Pagani, (unknown), Alessandro Re, Giuseppe Rossi
17
18
Impact Of Posaconazole Prophylaxis On Invasive Fungal Infection During Acute Myeloid Leukemia Induction Therapy: Correlation With Posaconazole Serum Levels
2013 ·Blood ·Chiara Cattaneo, Erika Borlenghi, (unknown), (unknown), (unknown), Francesca Schieppati, Elisa Cerqui, Chiara Pagani, Alessandro Re, Giuseppe Rossi
2
19
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)
2011 ·Journal of Antimicrobial Chemotherapy ·Chiara Cattaneo, Suzanne M. de la Monte, Alessandra Algarotti, Ernesta Audisio, Erika Borlenghi, Leonardo Campiotti, Elisa Cerqui, Caterina Fanizza, R. Giuliani, Caterina Micò, Rodney P. Rocconi, Aldo Salvi, Francesca Salvi, Luisa Verga, Alessandro Levis, (unknown), Enrico Maria Pogliani, Gianni Tognoni, Alessandro Rambaldi, Giuseppe Rossi
24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppina Loglisci Breakdown of academic impact, for papers by Federica Lessi Breakdown of academic impact, for papers by Kazuya Ishiwata Breakdown of academic impact, for papers by M.L. Martino Breakdown of academic impact, for papers by José Falantes Breakdown of academic impact, for papers by Stefano D’Ardìa Breakdown of academic impact, for papers by Nadira Duraković Breakdown of academic impact, for papers by Radwan Massoud Breakdown of academic impact, for papers by Sigrid Machherndl‐Spandl Breakdown of academic impact, for papers by Felipe Sandoval
Rankless by CCL
2026